Clinical trials / NCT05877963
NCT05877963Phase 3Recruiting

Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

Study sponsor: TG Therapeutics, Inc. · TGTX

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov recordCSV export · Pro
Primary completion2027-01-21Estimated
Enrollment · participants800Estimated
Source updated2026-09-21Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 1 field changed

Primary completion date changed

− Before

1 Dec 2027

+ After

21 Jan 2027

Check registry source

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Part A: Percentage of Participants With no Change or Reduction in Number of T1 Gd-Enhancing Lesions From Baseline to Week 48 Measure: Part B: Area Under the Curve Over the First 16 Weeks (AUC0-W16) of Ublituximab

+ After

Measure: Part A and Part C: Percentage of Participants With no Change or Reduction in Number of T1 Gd-Enhancing Lesions From Baseline to Week 48 Measure: Part B: Area Under the Curve Over the First 16 Weeks (AUC0-W16) of Ublituximab

Primary completion date changed

− Before

1 Sep 2026

+ After

1 Dec 2027

Check registry source

· 2 fields changed

Planned enrollment increased by 200 participants

− Before

600 participants (planned)

+ After

800 participants (planned)

Primary completion date changed

− Before

1 Mar 2026

+ After

1 Sep 2026

Check registry source